EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20

March 21, 2018 - By Adrian Mccoy

 EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20
Investors sentiment decreased to 1.17 in Q3 2017. Its down 1.32, from 2.49 in 2017Q2. It is negative, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Teachers Retirement Sys Of The State Of Kentucky owns 11,000 shares. 7,248 were reported by State Of Alaska Department Of Revenue. Glenmede Trust Na reported 0% stake. Macquarie Gru Limited reported 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Texas Permanent School Fund accumulated 26,706 shares. Geode Mngmt Limited Liability Corporation stated it has 395,969 shares. Prelude Capital Ltd Liability Corporation holds 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO) or 9,134 shares. D E Shaw & reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Thrivent Financial For Lutherans accumulated 22,390 shares or 0% of the stock. Legal & General Public Ltd Company has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Trexquant L P reported 0.04% stake. Nordea Management holds 0.01% or 126,040 shares in its portfolio. 95,022 were accumulated by Cap One Association. Employees Retirement Systems Of Texas owns 30,000 shares or 0.01% of their US portfolio. Menta Lc stated it has 0.1% in AngioDynamics, Inc. (NASDAQ:ANGO).

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 20.95 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 0.18% or $0.03 during the last trading session, reaching $16.76. About 391 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 21, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Hold” rating by KeyBanc Capital Markets given on Thursday, August 24. Zacks upgraded the stock to “Sell” rating in Monday, August 31 report. The rating was maintained by Canaccord Genuity on Sunday, October 8 with “Hold”. On Wednesday, September 23 the stock rating was initiated by Sidoti with “Neutral”. The firm earned “Hold” rating on Thursday, September 28 by KeyBanc Capital Markets. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, July 19. The rating was reinitiated by Piper Jaffray on Friday, April 8 with “Neutral”. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) on Thursday, January 4 with “Hold” rating. The rating was initiated by Cantor Fitzgerald on Friday, November 4 with “Buy”. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Tuesday, July 18. Canaccord Genuity has “Hold” rating and $1700 target.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $615.85 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.